StockData
Telix Pharmaceuticals Ltd logo

Telix Pharmaceuticals Ltd (TLX) stock

TLXNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as TLPPF
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Feb 20, 2026Score 3/30
$9.23−0.13 (-1.39%)

Close on Nov 13, 2026Market cap $3.13BP/E –Yield –

Earnings

Telix Pharmaceuticals's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
–
Not yet scheduled
Revenue, Q2 FY2026
$477.00M
EPS, Q2 FY2026
–
Latest guidance
Issued
Aug 20, 2026 · 2 items

Quarterly results

Revenue and earnings per share from each of Telix Pharmaceuticals's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q2 FY2026ended Jun 30, 2026Aug 20, 2026after the close$477.00M––Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Telix Pharmaceuticals's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
revenue guidanceFY2026$950.00M – $970.00M–NewAug 20, 2026
R&DFY2026$230.00M – $270.00M–NewAug 20, 2026

Guidance history

Every forecast Telix Pharmaceuticals put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Aug 20, 2026R&DFY2026$230.00M – $270.00MNew
Aug 20, 2026revenue guidanceFY2026$950.00M – $970.00MNew

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Telix Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K

  1. A radiopharmaceutical powerhouse with enhanced capabilities across the value chain Telix + ITM Telix Pharmaceuticals ASX: TLX | NASDAQ: TLX Updated October 27, 2026 Appendix A: Investor Presentation
    6-K
  2. 6-K exhibit EX-99
    6-K
  3. 6-K exhibit EX-99.1
    6-K
  4. A radiopharmaceutical powerhouse with enhanced capabilities across the value chain Telix + ITM Telix Pharmaceuticals ASX: TLX | NASDAQ: TLX September 21, 2026
    6-K
  5. 6-K exhibit EX-99.1
    6-K
  6. 6-K exhibit EX-99.1
    6-K
  7. 6-K exhibit EX-99.1
    6-K
  8. H1 2026 Interim Results Presentation August 20, 2026 ASX: TLX | NASDAQ: TLX Radiopharmaceutical manufacturing suite at TMS North Melbourne.
    6-K
  9. 6-K exhibit EX-99.2
    6-K
  10. 6-K exhibit EX-99.3
    6-K
  11. 6-K exhibit EX-99.1
    6-K
  12. 6-K exhibit EX-99.1
    6-K
  13. 6-K exhibit EX-99.1
    6-K
  14. 6-K exhibit EX-99.2
    6-K
  15. 6-K exhibit EX-99.3
    6-K

See a number that looks wrong?